Biogen (NASDAQ:BIIB – Get Free Report) had its price target raised by equities research analysts at Barclays from $200.00 to $230.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price points to a potential downside of 7.87% from the company’s previous close.
Several other research analysts have also recently commented on the stock. Royal Bank Of Canada lowered their target price on shares of Biogen from $260.00 to $256.00 and set an “outperform” rating on the stock in a report on Thursday, October 8th. Zacks Research upgraded Biogen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Bank of America increased their price target on Biogen from $219.00 to $244.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Oppenheimer restated an “outperform” rating and set a $300.00 price objective on shares of Biogen in a research note on Wednesday, July 29th. Finally, Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $251.00.
View Our Latest Analysis on Biogen
Biogen Trading Up 2.3%
Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same period in the prior year, the company posted $4.81 earnings per share. Biogen’s revenue was up 10.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Biogen will post 12.46 EPS for the current year.
Hedge Funds Weigh In On Biogen
Several hedge funds and other institutional investors have recently made changes to their positions in BIIB. BlackRock Inc. acquired a new position in Biogen in the 2nd quarter worth about $3,453,878,000. Primecap Management Co. CA acquired a new stake in shares of Biogen during the second quarter valued at about $3,274,304,000. Wellington Management Group LLP boosted its stake in shares of Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after purchasing an additional 155,828 shares in the last quarter. Amundi boosted its stake in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after purchasing an additional 726,004 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Biogen during the second quarter valued at about $322,640,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.
Key Biogen News
Here are the key news stories impacting Biogen this week:
- Positive Sentiment: Q3 results beat expectations: Adjusted earnings were $2.62 per share versus the roughly $1.99 consensus, while revenue rose 10.6% year over year to $2.80 billion, ahead of estimates. Growth-portfolio revenue surged 49% to $1.26 billion, helped by Biogen’s newer treatments and the first full-quarter contribution from products acquired through Apellis. BIIB Q3 Earnings Beat, New Drugs Aid Sales
- Positive Sentiment: Analysts turned more bullish: Needham and Baird raised their targets to $290, UBS lifted its target to $300 while maintaining a Buy rating, and RBC raised its target to $272 with an Outperform rating. Argus upgraded BIIB from Hold to Buy with a $280 target; Canaccord also initiated a Buy-equivalent view with a $272 target. Analysts Increase Forecasts on Biogen
- Positive Sentiment: Improved earnings outlook: Biogen raised the low end of its 2026 adjusted EPS guidance to $12.20, while management characterized the business as having returned to growth. RBC said the solid results could support continued stock momentum. Biogen Swings Back to Growth
- Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data for its Alzheimer’s portfolio at CTAD 2026, including data on lecanemab and investigational diranersen that could provide additional visibility into future growth. Biogen to Present Alzheimer’s Data at CTAD 2026
- Neutral Sentiment: Morgan Stanley raised its target to $238 but retained an Equal Weight rating, while TD Cowen and Truist lifted targets to $260. These revisions signal better fundamentals but limited near-term upside from some analysts’ perspectives.
- Negative Sentiment: Biogen reported a GAAP net loss of $20.6 million, compared with a profit a year earlier, primarily because of acquisition-related research and development charges. Barclays also maintained an Equal Weight rating with a $230 target, and unusually heavy put-option activity indicates that some traders remain cautious.
About Biogen
Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.
The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.
Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Biogen
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
